caprotec is partnering with Genovative Solutions, LLC in the area of sales and marketing with its founder Jeff Protentis acting as caprotec's lead agent for North America.
The company also announced the appointment of Dr. Christian Jurinke as President of its US subsidiary caprotec Inc. Dr Jurinke, a 12 year veteran of developing and commercializing products for life science ventures, joined caprotec in 2008 to head the company's key product commercialization and help manage the company's growing distribution channels. Before joining caprotec Dr. Jurinke most recently served in a number of senior management positions at Sequenom, Inc. in San Diego.
"The opening of our US subsidiary is an important milestone in commercializing our CCMS technology," stated Dr. Hubert Koster, CEO of caprotec bioanalytics. "We have well-established distribution channels in Europe and Japan. The steadily increasing demand for our products in North America necessitated a US presence as the most effective and efficient strategy."
"Our US subsidiary is now fully operational to serve the North American proteomics research community with our growing family of products," said Dr. Jurinke. "Through our US subsidiary we can now rapidly execute the increasing amount of orders, and we are able to expand our operations as demand is increasing."
The company's caproKits address the needs of the proteomics community as a novel and direct way to investigate interactions of small molecules with proteins and are used to identify protein kinases, cAMP- and cGMP-binding proteins, methyl transferases or metallo-proteases directly from biological samples. In collaborations with pharmaceutical and biotech companies, caprotec uses its proprietary Capture Compound Mass Spectrometry (CCMS) technology to determine protein profiles of drug interactions to identify drug targets as well as side effect causing off-target proteins or to elucidate the mode of action.
About caprotec bioanalytics GmbH
caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds(TM). They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry or gel electrophoresis and Western blotting. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.
SOURCE caprotec bioanalytics GmbH
